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Damage to brain structures which constitute the distributed neural network that
integrates respiratory muscle and pulmonary functions, can impair adequate ventilation
and its volitional control. We tested the hypothesis that the level of brain pathology
in older adults is associated with declining respiratory function measured during life.
1,409 older adults had annual testing with spirometry (SPI) and respiratory muscle
strength (RMS) based on maximal inspiratory and maximal expiratory pressures (MEPs).
Those who died underwent structured brain autopsy. On average, during 5 years of
follow-up, SPI and RMS showed progressive decline which was moderately correlated
(ρ = 0.57, p < 0.001). Among decedents (N = 447), indices of brain neuropathologies
showed differential associations with declining SPI and RMS. Nigral neuronal loss was
associated with the person-specific decline in SPI (Estimate, −0.016 unit/year, S.E.
0.006, p = 0.009) and reduction of the slope variance was equal to 4%. By contrast,
Alzheimer’s disease (AD) pathology (Estimate, −0.030 unit/year, S.E. 0.009, p < 0.001)
and macroscopic infarcts (−0.033 unit/year, S.E., 0.011, p = 0.003) were associated
with the person-specific decline in RMS and reduction of the slope variance was equal
to 7%. These results suggest that brain pathology is associated with the rate of declining
respiratory function in older adults.
Keywords: aging, respiratory decline, respiratory muscles, spirometry, Alzheimer’s disease pathology, nigral
neuronal loss, macroscopic infarct, neuropathology
INTRODUCTION
To maintain adequate ventilation, a neural network integrates respiratory muscle and
pulmonary functions (Laviolette et al., 2013; Butler et al., 2014; Richter and Smith, 2014).
This distributed network begins in the brain and extends to the spinal cord where peripheral
nerves exit to innervate and activate respiratory muscles in the periphery (Laviolette et al.,
2013; Butler et al., 2014; Richter and Smith, 2014). Damage to brain structures which
constitute this distributed network may impair respiration separate from direct effects
on the respiratory muscles and intrinsic lung tissues. Furthermore, respiration is also
Frontiers in Aging Neuroscience | www.frontiersin.org 1 October 2015 | Volume 7 | Article 197
Buchman et al. Neuropathology and respiratory function in old age
under volitional brain control. Recent work in this cohort
and by others has shown that brain pathology is associated
with the progressive loss of motor function in older adults
(Gorelick et al., 2011; Jack et al., 2011; Stern et al., 2012; Boyle
et al., 2013; Buchman et al., 2014). It is unknown, if brain
pathology is also associated with declining respiratory function in
older adults.
We tested the hypothesis that the level of brain pathology
is associated with the rate of declining respiratory function
in older adults. We used data from 1,409 older persons
participating in a community-based cohort study that included
annual structured clinical exam and autopsy at death (Bennett
et al., 2012). Respiratory function was summarized using two
composite measures developed in a series of prior publications
(Buchman et al., 2008a,b, 2009; Boyle et al., 2009). Composite
spirometry (SPI) was derived from three spirometric measures
(vital capacity, VC; forced expiratory volume in 1 second, FEV1;
and peak expiratory flow, PEF). Composite respiratory muscle
strength (RMS) was based on maximal inspiratory pressures
(MIPs) and maximal expiratory pressures (MEPs). Post-mortem
indices of nine age-related brain pathologies were collected at
brain autopsy.
While SPI can be used to characterize restrictive or obstructive
lung disease, SPI will also vary with RMS. Moreover, the central
nervous system respiratory network integrates both intrinsic
lung function and RMS to maintain ventilation. Therefore, we
employed modeling which would account for the correlated
function of spirometric measures and RMS. Bivariate random
coefficient models were used to estimate simultaneously the rates
of change in composite measures of SPI and RMS. Then, using
data from decedents, we tested whether indices of degenerative




Participants are from the Rush Memory and Aging Project, a
community-based cohort study which began in Bennett et al.
(2012). The study was approved by the Institutional Review
Board of Rush University Medical Center. Written informed
consent and an anatomic gift act for brain donation at the time
of death was obtained from all study participants.
A completed baseline with respiratory testing has been
obtained in 1,754 participants examined since it was added
in 2001. This study excluded 345 individuals lacking a 2nd
evaluation since it focuses on change in respiratory function.
These included individuals who died before their 2nd visit,
had not been in the study long enough for follow-up, or valid
measures were not available. The 1,409 included in these analyses
had an average of 5 follow-up assessments (mean = 5.0, SD = 3.4).
Baseline age, education, SPI and RMS testing were similar in
participants with 5 or less follow-ups vs. those with more than
5 (results not shown), but there were more males with 5 or
less follow-ups (27.7% vs. 22.2%, Chi-square = 5.0863, df = 1,
p = 0.024).
Assessment of Respiratory Function
An annual uniform structured evaluation included medical
history and clinical examination by trained registered nurses
(Bennett et al., 2012).
SPI: two trials obtained with a hand-held spirometer which
measured VC, FEV1 and PEF (MicroPlus Spirometer MS03,
MicroMedical Ltd. Kent, UK). A composite SPI score was based
on the average of the z scores for VC, FEV1 and PEF as described
in prior publications Buchman et al. (2008a,b, 2009) and Boyle
et al. (2009).
RMS: muscles needed for adequate respiration include the
diaphragm and intercostal muscles which are innervated by
cervical and thoracic root segments not involved in limb
movements. One can isolate and estimate RMS by measuring
the maximal pressures generated during isometric inspiration
and expiration (Kim and Sapienza, 2005). A hand-held device
that contains a pressure sensitive transducer was used to assess
MIP and MEP in cm H2O (MicroMouth Pressure Meter MP01;
MicroMedical Ltd., Kent, UK). Two trials of both were obtained.
A composite RMS score was computed from the average of the z
scores for MIPs and MEPs (Buchman et al., 2008a,b, 2009; Boyle
et al., 2009). Since self-report pulmonary disease history was not
collected in MAP, possible pulmonary disease was considered
if the ratio of FEV 1 /FVC was <0.7, as suggested by previous
literature (Iqbal et al., 2002).
Comorbidities and Other Covariates
Age at enrollment, sex and years of education were recorded at
the baseline interview. Seven chronic diseases were documented
at baseline and each follow-up visit based on self-report of
hypertension, diabetes, myocardial infarction, cancer, thyroid
disease, head trauma, stroke and smoking status. Respiration
could be affected in participants who were receiving one or
more medications used to treat chronic pulmonary diseases
including anticholinergics, α-adrenergics, theophylline, steroid
inhalants, and leukotrienes; medications for Alzheimer’s
disease (AD) including central acetylcholinesterase inhibitors
(e.g., donepezil), NMDA receptor blockers (e.g., memantine),
parasympathomimetic agents (e.g., rivastigmine), alkaloid (e.g.,
galantamine) or medications for Parkinson’s disease (PD)
including levodopa or dopaminergic agonists, anticholinergics,
monoamine oxidase inhibitor (e.g., rasagiline), catechol-O-
Methyltransferase inhibitor (e.g., entacapone), NMDA receptor
antagonist (e.g., amantadine). Medications were inspected and
coded using the Medi-Span system (Medi-Span, Inc.; Buchman
et al., 2008b).
Post-Mortem Indices
Brain removal, tissue sectioning and preservation, and a uniform
gross and microscopic examination with quantification of post-
mortem indices followed a standard protocol (Bennett et al.,
2012). Nine post-mortem indices were examined.
Indices of cerebrovascular disease (CVD) pathologies which
assessed parenchymal and cerebral vessel pathology were
collected. We assessed the presence of macroscopic infarcts. We
reviewed 1 cm slabs and recorded the age, volume (in mm3),
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side, and location of all cerebral infarcts visible to the naked
eye as previously reported (Schneider et al., 2003). Hemorrhagic
infarcts were included in analyses. There was no minimum size
required for macroscopic infarcts. All grossly visualized and
suspected macroscopic infarcts were microscopically reviewed
for histologic confirmation. Infarct age (acute, subacute and
chronic) was estimated by gross histologic features and degree
of cavitation. In all cases we examined for the presence
of microinfarcts: (Arvanitakis et al., 2011). The following
regions were dissected, processed and embedded for review:
middle frontal cortex middle temporal cortex, anterior cingulate
cortex, inferior parietal cortex, entorhinal cortex, hippocampus,
anterior basal ganglia, anterior thalamus, and hemisection of
midbrain including substantia nigra. Hematoxylin and eosin
stained six micron sections were used to identify microscopic
infarcts. Microscopic infarcts were defined as any infarct
seen only by microscopic examination. Microscopic infarcts
ranged from cavitated to a focal area of shrinkage due
to astrogliosis associated with few remaining macrophages.
Any chronic microinfarct visualized microscopically by the
neuropathologist was included in our analyses. The quantity
of macroinfarcts and microinfarcts, were summarized using a
two level predictor measure: as absent or present as previously
described in Schneider et al. (2003) and Arvanitakis et al.
(2011).
Assessment for cerebral vessel pathology was also
systematically conducted, including for large and small
vessels. Atherosclerosis in the circle of Willis was assessed
on gross examination. Severity was graded on a scale from 0 (no
atherosclerosis) to 6 (severe atherosclerosis, with all visualized
arteries affected or one artery completely occluded).
Arteriolosclerosis was documented on H&E stained sections
of the anterior basal ganglia (caudate, putamen, globus pallidus,
and internal capsule) (10). Severity of this pathology was also
graded, and ranged from 0 (no arteriolosclerosis) to 6 (severe
or complete small vessel occlusion). For the purpose of analyses
for this study, severity of both these vessel pathologies were
grouped into four levels: not present, mild, moderate, and
severe.
Cerebral amyloid angiopathy (CAA) was determined
on immunohistochemical examination of meningeal and
parenchymal vessels in five neocortical regions (midfrontal,
middle temporal, angular and calcarine cortices). Slides were cut
from paraffin embedded blocks and stained with one of three
antibodies to amyloid beta [10D5 Beta Amyloid, 17–24 (4G8)
Covance Madison, 1:9000; Anti-Human Amyloid-Beta 1–16
(10D5) Elan Pharmaceuticals, San Francisco, 1:300; Anti-Human
Beta-Amyloid, (6F/3D), DAKO North America, Carpinteria,
1:50]. For each region, vascular deposition of amyloid beta was
scored from 0 (no deposition) to 4 (circumferential deposition
more than 75% of the region). The maximum score between
the meningeal and parenchymal amyloid angiopathy scores
was used as the amyloid angiopathy pathology score for that
region. Scores were then averaged across the five regions. We
used this overall average score to develop a four level rating
scale, based on the data distribution and pathology severity
at the different levels as determined by the neuropathologist.
For analyses in this study, we used amyloid angiopathy
severity data categorized as none, mild, moderate, and severe
grades.
AD pathology was assessed in the frontal, temporal, parietal,
and entorhinal cortex, and the hippocampus, as previously
described in Bennett et al. (2006). Bielschowsky silver stain
was used to visualize neuritic plaques, diffuse plaques, and
neurofibrillary tangles. Briefly, the operator used a graticule to
project a grid to count numbers of each pathological marker
in a 1 mm2 area (magnification ×100) under the microscope.
Counts were performed by a board-certified neuropathologist
or trained technician blinded to all clinical data. Plaques and
tangle counts had different ranges and were not normally
distributed; therefore, we created standardized scores for each
plaque and tangle count in each cortical area as previously
described. These scaled scores for each region were then
averaged across the five regions (midfrontal, superior temporal,
inferior parietal, entorhinal, and hippocampal cortex) to develop
summary scores for diffuse plaques, neuritic plaques, and
neurofibrillary tangles for each subject. We then averaged
the summary scores of the three AD markers from the five
sites examined to yield the global measure of AD pathology
for each subject used in these analyses (Bennett et al.,
2006).
Transactive response DNA-binding protein 43 (TDP-
43) was assessed in six brain regions (amygdala, entorhinal
cortex, CA1/subculum, dentate gyrus, middle temporal
cortex, midfrontal cortex) with a monoclonal antibody to
phosphorylated TDP-43 (pS409/410; 1:100; Neumann et al.,
2009). In each region, neuronal and glial TDP-43 cytoplasmic
inclusions were rated on a six-point scale from none to severe,
and regional ratings were averaged to yield a total score (Wilson
et al., 2013).
PD pathology was based on the assessment of nigral neuronal
loss and the presence of Lewy body pathology. Dissection of
diagnostic blocks included a hemisection of midbrain which
included substantia nigra. Nigral neuronal loss was assessed in
the substantia nigra in the mid to rostral midbrain near or at the
exit of the 3rd nerve using H&E stain and 6micron sections using
a semi-quantitative scale (0–3) was employed and used in these
analyses (Buchman et al., 2012). Lewy body disease pathology
was identified with antibodies to alpha-synuclein using alkaline
phosphatase as the chromogen. The presence or absence of Lewy
body pathology was based on assessment of six brain regions
including substantia nigra, limbic cortex, and several neocortical
regions as previously described. A four level semiquantitative
measure for nigral neuronal loss was employed (Buchman et al.,
2012).
Statistical Analyses
Pairwise associations of baseline SPI and RMS with demographic
variables were examined using Pearson correlations. Declining
SPI and RMS occur simultaneously in the same individuals
and since they are controlled by a common network and share
volitional brain control they are likely to manifest correlated
function. Therefore, we employed bivariate random coefficient
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models which used the repeated clinical observations to estimate
the correlation structure between SPI and RMS. This single
model examines the associations of baseline level of each
outcome with their rates of change and the extent to which
simultaneous change in both of these outcomes are associated.
We elected not to include quadratic change because both fit
statistics of Akaike’s Information Criterion (AIC) and Bayesian
Information Criterion (BIC) suggest that linear change was
sufficient. In addition, assessment of plots of a random sample
of participants did not show evidence of non-linearity.
Bivariate random coefficient models which adjusted for age,
sex and education were used to estimate simultaneously the levels
and rates of change of SPI and RMS. The correlation of level and
change in SPI and RMS was estimated from a joint distribution
of the random effects.
Using similar analyses in decedents, we added terms for
postmortem indices and estimated to what extent post-mortem
indices alone and together were associated with the trajectories
of SPI and RMS during life. Models were examined graphically
and analytically and assumptions were judged to be adequately
met. A priori level of statistical significance was 0.05. Programing
was done in SAS version 9.3 (SAS Institute Inc, Cary, NC, USA;
SAS Institute Inc, 2002–2003).
RESULTS
Descriptive Properties of Respiratory
Function in Older Adults
Clinical characteristics of participants included in these analyses
are in Table 1.
SPI at baseline ranged from−2.35 to 3.20 with amore positive
value indicative of better function, on average SPI was 0.02
(SD = 0.92). SPI was associated with age (r = −0.32; p < 0.001)
and education (r = 0.23, p < 0.001). At baseline, SPI was higher
in men (t489 =−20.14, p< 0.001).
RMS at baseline ranged from −2.13 to 3.41 with a more
positive value indicative of better strength, on average respiratory
TABLE 1 | Clinical characteristics of participants in these analyses.
Variable All (N = 1409) Alive (N = 843) Deceased (N = 566)
Mean (SD) Or N (%) Mean (SD) Or N (%) Mean (SD) Or N (%)
Demographics
Age at baseline (years) 80.1 (7.60) 77.8 (7.77) 83.6 (5.79)
Age at last visit/death (years) 85.1 (7.76) 83.3 (8.14) 89.6 (6.07)
Sex (female) 1047 (74.3%) 664 (78.8%) 383 (67.7%)
Education (years) 14.6 (3.17) 14.7 (3.32) 14.4 (2.92)
Clinical diagnoses
No cognitive impairment (NCI) 1012 (71.8%) 666 (79.0%) 346 (61.1%)
Mild cognitive impairment (MCI) 335 (23.8%) 163 (19.3%) 172 (30.4%)
AD dementia 62 (4.4%) 14 (1.7%) 48 (8.5%)
Parkinson’s disease 21 (1.5%) 6 (0.7%) 15 (1.6%)
Pulmonary function tests
Forced expiratory volume (L) 1.7 (0.56) 1.8 (0.55) 1.5 (0.54)
Vital capacity (L) 1.9 (0.62) 2.0 (0.61 1.8 (0.61)
Peak expiratory flow (L/min) 266.7 (111.64) 286.8 (109.45) 236.9 (108.27)
FEV/VC 0.9 (0.09) 0.9 (0.08) 0.8 (0.10)
Maximal inspiratory pressure (mm H2O) 41.7 (20.61) 45.2 (21.15) 36.3 (18.57)
Maximal expiratory pressure (mm H2O) 67.1 (24.57) 70.0 (24.86) 62.8 (23.49)
COPD (FEV/VC <0.7) 76 (5.4%) 26 (3.1%) 50 (8.8%)
Self-report medical conditions 1.4 (1.06) 1.4 (1.01) 1.6 (1.12)
Hypertension 757 (53.73%) 443 (52.6%) 314 (55.5%)
Diabetes 181 (12.85%) 102 (12.1%) 79 (14.0%)
Myocardial infarction 151 (10.73%) 61 (7.25%) 90 (15.9%)
Cancer 440 (31.23%) 263 (31.2%) 177 (31.3%)
Thyroid disorder 278 (19.74%) 168 (20.0%) 110 (19.4%)
Head trauma 88 (6.25%) 53 (6.29%) 35 (6.19%)
Stroke 132 (10.32%) 56 (7.73%) 76 (13.7%)
Post-mortem indices (N = 447)
Post-mortem interval (hrs) 8.35 (7.41)
Chronic macroinfarct (1 or more) 167 (37.4%)
Chronic microinfarct (1 or more) 138 (30.9%)
Atherosclerosis (moderate-severe) 159 (35.7%)
Arteriolosclerosis (moderate-severe) 158 (35.5%)
Cerebral amyloid angiopathy 152 (34.2%)
Alzheimer’s disease (based on NIA reagan) 285 (63.8%)
TDP-43 220 (53.5%)
Lewy body disease present 100 (22.4%)
Nigral neuronal loss (moderate-severe) 55 (12.3%)
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FIGURE 1 | Change in spirometry (SPI) and respiratory muscle strength (RMS) and the effect of more brain pathology on their rates of change. The left
panels show change in SPI (top) and RMS (bottom) during the study. Crude paths of change (gray lines) and mean paths of change predicted by the model (black
lines) in SPI (top) and RMS (bottom). To facilitate visualization data from a 25% random sample of decedents is illustrated in the left panels. To display the association
of brain pathology on the rate of change in respiration, four hypothetical average participants with their estimated rate of declining respiration based on the model
which included all the cases analyzed in this study are illustrated. The right panels show the model derived predicted paths of SPI (top) and RMS (bottom) for four
participants with increasing burden of brain pathology: (1) Black line, the predicted path for a participant with No pathology; (2) Red line, the predicted path for a
participant with Alzheimer’s disease (AD) pathology; (3) Green line, the predicted path for a participant with AD pathology and macroinfarcts; (4) Blue line, the
predicted path for a participant with AD pathology, macroinfarcts and severe nigral neuronal loss.
function was 0.01 (SD = 0.91). RMS was associated with age
(r = −0.28; p < 0.001) and education (r = 0.13, p < 0.001). At
baseline, RMS was higher in men (t537 =−15.97, p< 0.001).
Rates of Change in Spirometry and
Respiratory Muscle Strength in Older
Adults
During up to 13 years of follow-up, both SPI (Estimate −0.068,
S.E. 0.002, p < 0.001) and RMS (Estimate −0.050, S.E. 0.002,
p < 0.001) declined. Observed paths of change (gray lines)
and model estimated mean paths of change (black) in SPI
(top) and RMS (bottom) are illustrated on the left panel of
Figure 1.
Person-specific rates of change of SPI and RMS was
moderately correlated (Table 2). Figure 2 is a two-dimensional
histogram of the model derived annual rates of change in SPI
and RMS (left), and the corresponding density map (right).
The figures highlight the relationship between declining SPI
and RMS.
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FIGURE 2 | Annual rates of change in SPI and RMS. On the left is a two-dimensional histogram of annual rates of change in SPI and RMS estimated by
simultaneous random effects model (Table 2). The figure on the right depicts the density of the number of participants shown in the two dimensional histogram with
yellow showing increased density compared to the shades of red. X axis shows change in SPI and Y axis shows the change in RMS. In both portions of the figure,
each point illustrates the person-specific change in both aspects of respiratory function. As can be seen on the right, nearly all values are less than zero, for SPI and
RMS since both declined in nearly all cases.
The rates of change remained associated when adjusting for
demographics (r = 0.49, p < 0.001). In these models, increasing
age and male sex, but not education were associated with more
rapid decline in SPI and RMS (p’s< 0.001).
In further analyses, we examined each of the individual
measures used to construct these composite measures. Each of
the individualmeasures declined and showed similar associations
with age and sex (Table 3).
Poor health and smoking can affect respiration. Controlling
for the number of chronic health conditions present at baseline
TABLE 2 | Correlation of baseline and longitudinal changes in spirometry
and respiratory muscle strength.
Variable Respiratory Change in Change in
muscle spirometry respiratory muscle
strengthbl strength
Spirometrybl 0.63∗ −0.26∗ −0.13
Respiratory – 0.05 −0.25∗
Muscle strengthbl
Change in spirometry – 0.57∗
Estimated correlation (∗p < 0.002) between of the baseline and longitudinal terms
included in the simultaneous bivariate random coefficient models (Figure 2). The
core model included terms for baseline spirometry and respiratory muscle function
and their interaction with Time i.e., the rate of change in spirometry and the rate of
change in and respiratory muscle function.
and a history of present or past smoking did not account for
the correlation of the rate of change in SPI and RMS (r = 0.51,
p< 0.001).
Level of physical activity might also affect respiration. The
correlation of the rate of change in SPI and RMS was unchanged
when we controlled for self-reported physical activity (r = 0.49,
p< 0.001).
The use of pulmonary medications could affect respiration.
Controlling for pulmonary medications did not attenuate the
correlation of declining SPI and RMS (r = 0.49, p < 0.001).
Adjustment for treatment with AD or PD medications did not
affect the correlation of declining SPI and RMS (AD: r = 0.49,
p< 0.001; PD: r = 0.48, p< 0.001).
In a series of sensitivity analyses, the rates of change in SPI and
RMS remained strongly associated when we excluded cases with
clinical dementia at baseline (N = 62, 4.4%; r = 0.46, p < 0.001);
PD (N = 21, 1.5%; r = 0.50, p< 0.001) and stroke (N = 132, 10.3%;
r = 0.46, p< 0.001).
Brain Pathology and Rates of Change in
Spirometry and Respiratory Muscle
Strength in Older Adults
Since respiration is controlled by a distributed CNS network
and is subject to volitional control, we examined whether
indices of brain pathologies were associated with the rates of
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TABLE 3 | Linear-mixed effect models showing the effect of demographic variables on the rate of change of spirometric measures, MIPs and MEPs in
community-dwelling older adults.
Spirometry Respiratory muscle strength
Model term PVC FEV PEF MEP MIP
Annual rate of change −0.069 −0.066 −0.052 −0.046 −0.043
0.003, <0.001 0.003, <0.001 0.003, <0.001 0.003, <0.001 0.003, <0.001
Age × annual rate of change −0.001 −0.001 −0.001 −0.001 −0.001
0.0003, <0.001 0.0003, <0.001 0.0003, 0.005 0.0004, <0.001 0.0004. 0.018
Sex × annual rate of change −0.021 −0.025 −0.022 −0.023 −0.020
0.006, <0.001 0.005, <0.001 0.006, <0.001 0.007, <0.001 0.006, 0.001
Education × annual rate of change −0.001 −0.001 −0.0003 −0.0005 0.001
0.001, 0.189 0.001, 0.061 0.009, 0.700 0.001, 0.613 0.001, 0.195
Linear-mixed effect models were performed for each of the 3 components (vital capacity, forced expiratory volume, peak expiratory force) used to construct composite
spirometry and the two components used to construct composite respiratory muscle strength (RMS; maximal expiratory pressure, MEP and maximal inspiratory pressure,
MIP). Each model included a term for Time in years since the baseline which quantifies the rate of change in the spirometry or RMS measure which was being examined.
To control for the effect of demographic variables, we also included terms for age, sex and education and their interaction with the annual rate of change in the respiratory
measure which was examined. The cross sectional terms which were included in these models are not shown in this table. The mean annual rate of change in standardized
units for spirometric measures was larger than for RMS measures [PVC: −0.07 (SD = 0.02); FEV: −0.07 (SD = 0.02); PEF: −0.06 (SD = 0.02); MEP: −0.05 (SD = 0.02);
MIP: −0.05 (SD = 0.02)].
change in SPI and RMS. There were 566 cases (31.8%) who
died during the study and 478 (84.5%) underwent a uniform
structured brain autopsy which has been completed in the first
447 consecutive individuals. A summary of the baseline clinical
characteristics of those who died vs. those who did not die and
post-mortem indices are included in Table 1. At their last visit,
about 40% of those undergoing autopsies had clinical dementia
[AD (N = 154, 34.7%; vascular dementia N = 10, 2.3%; Lewy
body dementia N = 7; 1.6%; other N = 4, 1.0%)]. The average
participant had three different pathologies; almost all (>97%)
had 1 or more pathologies (1 = 13.7%; 2 = 19.2%; 3 = 20.8%;
4 = 22.4%; 5 = 13.2%, 6 or more 7.8%). Older age at death was
associated with the presence of more brain pathologies (r = 0.19,
p< 0.001).
First, we examined if SPI and RMS showed correlated change
in participants who died. We repeated the core model (Table 2)
and adjusted for demographics in deceased participants who
underwent autopsy. The simultaneous change in lung function
and RMS was strongly related (r = 0.61, p < 0.001). The rates of
declining SPI and RMS was more rapid in males (p’s< 0.02), but
did not vary with age or education.
Next, we compared the rates of change between SPI and
RMS between participants who died and those who remained
living. Those who died showed more rapid declining SPI
(Estimate −0.024, S.E., 0.005, p < 0.001) and RMS (Estimate
−0.018, S.E., 0.005, p = 0.001). While the rate of respiratory
decline was about 40% more rapid in those who died compared
to those who did not die, the correlated change between
the rates of declining SPI and RMS remained significant in
both groups (r = 0.45, p < 0.001). To determine if brain
neuropathologies were associated with declining SPI and RMS,
in separate models, we added terms for each of the 9 post-
mortem indices as well as their interaction with time to
the core model described above (Table 4). Three of the
nine pathologies (nigral neuronal loss, AD pathology and
macroinfarcts) remained associated with the rate of change
of either SPI or RMS when included together with the other
pathologies.
Brain pathologies were differentially associated with declining
respiratory function. Nigral neuronal loss was strongly associated
with the rate of change in SPI and there was a marginal
association for Lewy body pathology and macroinfarcts. The
presence of macroinfarcts and AD pathology were independently
associated with the rate of change in RMS and there was a
marginal association for nigral neuronal loss (Table 5).
Given the sex differences observed in the rate of respiratory
decline, we examined whether the associations of brain
pathologies and declining respiration varied with age or sex by
adding three-way interaction terms to the model summarized in
Table 5. The associations of these brain pathologies with the rate
of change in SPI and RMS did not vary with age or sex (results
not shown).
The right panels of Figure 1 illustrate the additive effects
of these pathologies on the rate of change of SPI and RMS
by showing the trajectories for four average participants with
increasing burden of neuropathology. In the model with nigral
neuronal loss, reduction of the person-specific SPI slope variance
was equal to 4%. In contrast, in the model with AD pathology
and macroinfarcts, reduction of the person-specific RMS slope
variance was equal to 7% (Table 6).
DISCUSSION
Late-life motor impairment is common and progressive in
many older adults with a marked heterogeneity in its rate
of progression (Kim and Sapienza, 2005; Rosso et al., 2013).
Respiratory function requires the integrated actions of intrinsic
lung function and respiratory muscles to maintain adequate
ventilation. Cross sectional studies have shown that assessment
of respiration with SPI and RMS based on MIPs and MEPs show
lower levels with increasing age (Enright et al., 1994; Sclauser
Pessoa et al., 2014). While, longitudinal studies have shown
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TABLE 4 | Associations of individual brain pathologies and the annual rate of change in spirometry and respiratory muscle strength.
Model Pathology Pathology × annual rate of Pathology × annual rate of change in
change in spirometry respiratory muscle strength
Estimate Estimate
(S.E., p-Value) (S.E., p-Value)
1 Macroinfarcts −0.018 −0.030
(0.010, 0.088) (0.011, 0.009)
2 Microinfarcts −0.006 −0.025
0.010, 0.566 0.011, 0.030
3 Alzheimer disease 0.003 −0.029
0.008, 0.668 0.009, 0.002
4 Lewy body disease −0.024 −0.014
0.012, 0.037 0.013, 0.269
5 Nigral neuronal loss −0.017 −0.011
0.006, 0.005 0.007, 0.093
6 Atherosclerosis −0.009 −0.005
0.006, 0.129 0.006, 0.462
7 Arteriolosclerosis −007 −007
0.006, 0.195 0.006, 0.262
8 Cerebral amyloid angiopathy −0.008 −0.010
0.005, 0.117 0.006, 0.061
9 TDP-43 −0.005 −0.004
0.005, 0.299 0.005, 0.478
Each row shows the results estimated from simultaneous bivariate random coefficient models which included terms for baseline and rate of change in spirometry (SPI) and
RMS. Each of the nine models included terms to control for demographics (age, sex, education) and for each brain pathology alone. This table only shows the interaction
between brain pathologies and the rates of change in spirometry, RMS and the correlation between the rates of change in spirometry and RMS. The other terms (age,
sex and education) included in the model and the other interaction terms are not shown.
that spirometric measures decline in older adults, these studies
have not reported concurrent assessments of RMS (Tang et al.,
2013, 2014). In prior studies in this cohort, we examined the
inter-relationship of concurrent spirometric and RMS measures
in older adults at baseline and their association with survival,
mobility decline and incident disability (Buchman et al., 2008a,b,
2009). However, our prior studies did not examine the inter-
relationship of the rate of change in SPI and RMS measures over
time.
The current study extends these prior reports in several
important ways. Longitudinal studies of conventional motor
performances including gait and use of the extremities, dshow
that while most older individuals show some degree of decline
over time, some show stable function for many years (Buchman
et al., 2014). In the current study, we found that while there
is substantial inter-individual heterogeneity (Figure 1), nearly
all participants showed some degree of loss of spirometric and
RMS during the course of this study. Further work is needed to
delineate the mechanisms which underlie the progressive loss of
respiratory function.
Recent work in this cohort and by others has shown that
the accumulation of degenerative brain changes may contribute
to loss of a wide range of cognitive and motor abilities in
older adults (Gorelick et al., 2011; Jack et al., 2011; Stern
et al., 2012; Boyle et al., 2013; Buchman et al., 2014). While
it is well known that damage to brain structures can impair
adequate ventilation and its volitional control, we are unaware
of prior studies which have examined the relation of post-
mortem neuropathology and respiratory function measured
during life. The current findings provide novel data showing that
brain pathologies are also associated with declining respiratory
function. While TDP-43 may affect respiratory function in
ALS, in the current study of community-dwelling older adults
it was not associated with declining respiration (Pokrishevsky
et al., 2012). Other indices of neuropathology were associated
with respiratory function, but some were related to declining
SPI and others were related to RMS. Nigral neuronal loss
was associated with SPI, but not with RMS. Recent reports
have described possible lung dysfunction in classical PD
(Wang et al., 2014). Nigral neuronal loss can be caused by
a wide range of disease processes for example AD, PD and
CVD. In the current study Lewy body pathology was only
marginally associated with declining SPI. Since Lewy body
pathology only occurs in about 20% of cases, while up to
40% of older adults may have some degree of nigral neuronal
loss, more cases may be needed to determine whether there
is differential association of spiromtey and RMS with Lewy
body pathology as well as nigral neuronal loss, linking more
directly to PD (Buchman et al., 2012). By contrast, AD
pathology and macroinfarcts were associated with RMS but
not with SPI. This latter association extends prior reports
in this cohort of a link between decreased muscle bulk and
RMS in old age with incident mild cognitive impairment
(MCI) and AD (Buchman et al., 2005; Boyle et al., 2009;
Sanches et al., 2014). The varied associations observed in
the current study, underscores the importance of analyzing
different components of the respiratory network separately, since
these findings would not be apparent if only one aspect is
measured.
Degenerative brain changes explained about 4% of the
variance of declining SPI and 7% of declining RMS in the
current study. The bulk of respiratory decline was unexplained
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TABLE 5 | Brain pathologies independently associated with the annual rate of change in spirometry and respiratory muscle strength prior to death.
(A) Associations of brain pathologies with Associations of brain pathologies with
annual rate of change in annual rate of change in
spirometry (SPI) respiratory muscle strength (RMS)
Term Estimate (S.E., p-value) Term Estimate (S.E., p-value)
Macroinfarct × −0.018 Macroinfarct × −0.033
annual rate of change in SPI (0.010, 0.075) annual rate of change in RMS (0.011, 0.003)
AD pathology × 0.003 AD pathology × −0.030
annual rate of change in SPI (0.010, p = 0.718) annual rate of change in RMS (0.011, p < 0.001)
Nigral neuronal loss × −0.016 Nigral neuronal loss × −0.011
annual rate of change in SPI (0.006, p = 0.009) annual rate of change in RMS (0.007, p = 0.089)
(B) Interaction of brain pathologies with Interaction of brain pathologies with
annual rate of change in annual rate of change in
spirometry (SPI) respiratory muscle strength (RMS)
Term Estimate (S.E., p-value) Term Estimate (S.E., p-value)
Macroinfarct × −0.019 Macroinfarct × −0.033
annual rate of change in SPI (0.010, p = 0.072) annual rate of change in RMS (0.011, p < 0.003)
AD pathology × 0.003 AD pathology × −0.030
annual rate of change in SPI (0.008, p = 0.708) annual rate of change in RMS (0.009, p < 0.001)
Lewy body pathology × −0.022 Lewy body pathology × −0.013
annual rate of change in SPI (0.012, p = 0.056) annual rate of change in RMS (0.013, p = 0.313)
After we reviewed the results of the analyses summarized in Table 4, we examined a model which included the pathologies which showed an association with either the
rate of change in spirometry or RMS prior to death to determine which pathologies showed independent associations with declining respiratory function, (A,B) each show
the results estimated from a single simultaneous bivariate random coefficient models which included terms for baseline and the annual rates of change in spirometry and
RMS (Table 3) which adjusted for age, sex, education and their interaction with annual rates of change (not shown). In addition, these models included terms for the brain
pathologies and their interactions with the annual rates of change in spirometry and RMS. This table only shows the interaction between brain pathologies and the annual
rates of change in spirometry and RMS. We show models with nigral neuronal loss (A) and LBD pathology (B) separately because we have shown previously that nigral
neuronal loss may link LBD pathology with clinical outcomes.
by traditional brain pathologies, suggesting that unidentified
brain pathologies, disease processes or structures remain to be
identified to explicate the biology underlying respiratory decline
in older adults Given the extent of respiratory impairments in
old age, even the modest effect sizes observed in the current
study are likely to be important. It is worth comparing the
current results for declining respiration to cognitive decline
which derives exclusively from degenerative changes limited
to brain structures. In recent reports which have employed
a similar approach for examining the pathologic basis for
cognitive decline, AD pathology accounted for about 20% of the
variance of declining cognition in older adults. Other pathologies
TABLE 6 | Percentage of the variance of rate of change in spirometry and
respiratory muscle strength explained by demographics and post-mortem
indices.
Model term(s) Percentage of variance Percentage of variance
of change in of change in
spirometry respiratory
muscle strength
Age, Sex, Education 8.88% 17.02%
Neuropathologies 3.27% 7.37%
Macroinfarcts NS 6.27%
AD pathology NS 1.10%
Nigral neuronal loss 3.27% NS
Total % of variance 12.15% 24.39%
including Lewy body pathology and macroinfarcts accounted for
8% and 3% of the variance of cognitive decline (Boyle et al.,
2013; Buchman et al., 2014). The small percentage of variance
of respiratory function accounted for by brain pathology is
similar to findings for other volitional motor performance whose
pathways also extend beyond the brain (Buchman et al., 2014).
Since other central nervous system structures and many non-
neurologic constituents, e.g., intrinsic lung and muscle tissues,
are essential for respiration and other motor performances, it is
not surprising that degenerative brain changes only accounts for
a minority of the variance of declining respiratory and motor
function in older adults. Nonetheless, the current findings lend
support to the notion that degenerative brain changes may make
amore substantial contribution tomorbidity andmortality in old
age than previously suspected (James et al., 2014).
The study has strengths that lend confidence in the findings.
All subjects were recruited from the community and underwent
an annual detailed clinical evaluation. Uniform, structured
clinical and post-mortem procedures were followed by examiners
blinded to data collected at other visits. Clinical follow-up and
autopsy rates were very high. The analytic approach employed in
this study permitted simultaneous characterization of both cross
sectional and longitudinal association in the same individuals.
The availability of post-mortem indices provided an opportunity
to examine whether degenerative brain changes are associated
with declining respiration in older adults. Like all observational
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clinical-autopsy studies, these analyses cannot determine if the
association with pathology is causal or whether they are affected
by a latent variable or whether primary pulmonary diseases
could affect brain function. The large number of cases provided
sufficient power to evaluate demographic and clinical variables
that might have affected results.
This study has important limitations. First, participants were
selected by their willingness to participate in these studies and
their rates of chronic diseases may be lower than other studies
suggesting that they may not represent the general population.
Longitudinal studies of population-based samples are needed.
The study did not collect a comprehensive assessment of clinical
lung diseases underscoring the need for further studies which
can provide additional clinical characterization. White matter
abnormalities and other structural changes of the brain were not
included in these analyses and may explain additional variance
of declining respiratory function (Taki et al., 2013). Since most
of the post-mortem indices were obtained from different brain
regions the findings may underestimate the association CNS
pathologies located in brainstem and spinal cord locations which
comprise the respiratory network.
CONCLUSION
In this study, we assessed repeated measures of respiratory
function, based on SPI and RMS in more than 1,400 community-
dwelling older adults for up to 13 years. While there was
considerable variability in the person-specific trajectories of
change in respiratory function, nearly all participants exhibited
some degree of progressive decline of both SPI and RMS and their
rates of decline were moderately correlated. These data may have
important consequences for interventions to decrease declining
respiration in older adults. First, many older individuals may
require interventions not only for impaired lung function, but
are also likely to require care for concomitant respiratory muscle
weakness. Second, the strong correlation between spirometric
and RMS measures, lends support for clinical efforts to improve
respiratory function through RMS training in addition to
strategies to treat the causes of lung disease (Kim and Sapienza,
2005; Kulnik, 2015; Messaggi-Sartor et al., 2015).
Among those who died and underwent autopsy, indices of
brain pathologies were associated with declining respiration.
However, different brain pathologies were associated with
the measures of declining SPI and RMS, underscoring the
importance of assessing both constructs. Nigral neuronal loss
was associated with the rate of change of SPI. In contrast,
macroinfarcts and AD pathology were associated with declining
RMS. These novel data suggest that age-related brain pathologies
known to be associated with late-life cognitive and motor
impairment are also associated with declining respiration in
older adults. Linking respiratory decline with common brain
pathologies provides a host of new targets and pathways that may
lead to interventions for impaired respiration in older adults. For
example, that the association of PD pathology with respiratory
decline suggests that there may be a much larger number of
older adults without clinical PD whose respiratory function
may benefit from treatments developed for clinical PD or that
aggressive primary preventive therapies for CVDsmight slow the
rate of respiratory decline in older adults without clinical strokes
who may never report strokes.
FUTURE DIRECTIONS
Further work is needed to determine if the association between
brain pathology and respiratory decline is due to a third, latent
variable which causes brain pathology and respiratory decline
in older adults. If a latent variable is not identified, additional
studies will be necessary to delineate the causal direction of the
associations between brain pathology and respiratory decline
during life, since primary pulmonary disease can cause impaired
brain function. Answering these questions is essential before it
will be possible to explicate the mechanisms underlying these
associations.
The association between brain pathology and declining
respiration only reduced the slope variance by a small percentage.
This is similar to a prior study which examined other volitional
motor performances, whose CNS pathways also extend beyond
the brain (Buchman et al., 2014). The distributed neural networks
which control respiration are complex and extend from the brain
through specialized brainstem structures to the spinal cord to
exit the CNS via peripheral nerve to peripheral muscle and
pulmonary structures. In addition, these motor networks are
modulated by sensory feedback circuitries. Further studies are
needed to build on this study which focused on brain pathology.
It will be necessary to collect post-mortem indices from the
entire extent of the specialized structures which constitute the
distributed respiratory network to fully explicate the pathologic
basis underlying declining respiration in older adults.
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